Tokyo Tape
Sign in
← Koa Shoji Holdings

Half-year report · HY

9273.TEDINET S100XK39
Period2025-07-01 → 2025-12-31
Filed2026-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥12.7bn2025-07-01 → 2025-12-31Cons.Net sales
Revenue¥23.3bn2024-07-01 → 2025-06-30Cons.Net sales (5-year summary)
Revenue¥12.3bn2024-07-01 → 2024-12-31Cons.Net sales
Operating income¥3.2bn2025-07-01 → 2025-12-31Cons.Operating income
Operating income¥3.1bn2024-07-01 → 2024-12-31Cons.Operating income
Ordinary income¥3.1bn2025-07-01 → 2025-12-31Cons.Ordinary income
Ordinary income¥5.4bn2024-07-01 → 2025-06-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥3.1bn2024-07-01 → 2024-12-31Cons.Ordinary income
Profit before tax¥3.1bn2025-07-01 → 2025-12-31Cons.Income before income taxes
Profit before tax¥3.1bn2024-07-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)¥2.1bn2025-07-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.6bn2024-07-01 → 2025-06-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.0bn2024-07-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income¥2.1bn2025-07-01 → 2025-12-31Cons.Profit loss
Net income¥2.0bn2024-07-01 → 2024-12-31Cons.Profit loss
Total assets¥36.5bnat 2025-12-31Cons.Assets
Total assets¥36.1bnat 2025-06-30Cons.Assets
Total assets¥33.6bnat 2024-12-31Cons.Total assets (5-year summary)
Total liabilities¥7.0bnat 2025-12-31Cons.Liabilities
Total liabilities¥8.0bnat 2025-06-30Cons.Liabilities
Net assets / equity¥29.6bnat 2025-12-31Cons.Net assets
Net assets / equity¥28.1bnat 2025-06-30Cons.Net assets
Net assets / equity¥26.6bnat 2024-12-31Cons.Net assets (5-year summary)
Cash and deposits¥13.2bnat 2025-12-31Cons.Cash and deposits
Cash and deposits¥14.9bnat 2025-06-30Cons.Cash and deposits
Cash & equivalents¥13.0bnat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥14.7bnat 2025-06-30Cons.Cash and cash equivalents
Cash & equivalents¥9.8bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥13.2bnat 2024-06-30vCons.Cash and cash equivalents
Operating cash flow¥360m2025-07-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.8bn2024-07-01 → 2025-06-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2024-07-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2025-07-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.3bn2024-07-01 → 2025-06-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.7bn2024-07-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥829m2025-07-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥939m2024-07-01 → 2025-06-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥738m2024-07-01 → 2024-12-31Cons.Net cash provided by used in financing activities
EPS (basic)¥49.532025-07-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥86.382024-07-01 → 2025-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.662024-07-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio80.9%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio77.9%at 2025-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio79.1%at 2024-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-07-01 → 2025-12-31−¥649m
Reconciling Itemsreconcilingrevenue intersegment2025-07-01 → 2025-12-31−¥649m
Reconciling Itemsreconcilingsegment profit2025-07-01 → 2025-12-31¥46m
Drug Substance Sales Businessreportable segmentrevenue2025-07-01 → 2025-12-31¥8.5bn
Drug Substance Sales Businessreportable segmentrevenue external2025-07-01 → 2025-12-31¥7.8bn
Drug Substance Sales Businessreportable segmentrevenue intersegment2025-07-01 → 2025-12-31¥649m
Drug Substance Sales Businessreportable segmentsegment profit2025-07-01 → 2025-12-31¥1.8bn
Pharmaceutical Marketing Businessreportable segmentrevenue2025-07-01 → 2025-12-31¥4.8bn
Pharmaceutical Marketing Businessreportable segmentrevenue external2025-07-01 → 2025-12-31¥4.8bn
Pharmaceutical Marketing Businessreportable segmentsegment profit2025-07-01 → 2025-12-31¥1.3bn
—segment totalrevenue2025-07-01 → 2025-12-31¥13.3bn
—segment totalrevenue external2025-07-01 → 2025-12-31¥12.7bn
—segment totalrevenue intersegment2025-07-01 → 2025-12-31¥649m
—segment totalsegment profit2025-07-01 → 2025-12-31¥3.1bn
Reconciling Itemsreconcilingrevenue2024-07-01 → 2024-12-31−¥604m
Reconciling Itemsreconcilingrevenue intersegment2024-07-01 → 2024-12-31−¥604m
Reconciling Itemsreconcilingsegment profit2024-07-01 → 2024-12-31¥81m
Drug Substance Sales Businessreportable segmentrevenue2024-07-01 → 2024-12-31¥8.0bn
Drug Substance Sales Businessreportable segmentrevenue external2024-07-01 → 2024-12-31¥7.4bn
Drug Substance Sales Businessreportable segmentrevenue intersegment2024-07-01 → 2024-12-31¥604m
Drug Substance Sales Businessreportable segmentsegment profit2024-07-01 → 2024-12-31¥1.6bn
Pharmaceutical Marketing Businessreportable segmentrevenue2024-07-01 → 2024-12-31¥4.9bn
Pharmaceutical Marketing Businessreportable segmentrevenue external2024-07-01 → 2024-12-31¥4.9bn
Pharmaceutical Marketing Businessreportable segmentsegment profit2024-07-01 → 2024-12-31¥1.4bn
—segment totalrevenue2024-07-01 → 2024-12-31¥12.9bn
—segment totalrevenue external2024-07-01 → 2024-12-31¥12.3bn
—segment totalrevenue intersegment2024-07-01 → 2024-12-31¥604m
—segment totalsegment profit2024-07-01 → 2024-12-31¥3.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 495
ItemContextValueUnit
Net salesPrior1InterimDuration12259451000JPY
Net salesInterimDuration12654420000JPY
Cost of salesPrior1InterimDuration8102120000JPY
Cost of salesInterimDuration8296011000JPY
Gross profitPrior1InterimDuration4157331000JPY
Gross profitInterimDuration4358409000JPY
Selling general and administrative expensesPrior1InterimDuration1093853000JPY
Selling general and administrative expensesInterimDuration1189353000JPY
Operating incomePrior1InterimDuration3063478000JPY
Operating incomeInterimDuration3169055000JPY
Interest and dividends income noiPrior1InterimDuration2210000JPY
Interest and dividends income noiInterimDuration6861000JPY
Commission fee noiPrior1InterimDuration150000JPY
Commission fee noiInterimDuration2469000JPY
Compensation income noiPrior1InterimDuration33892000JPY
Compensation income noiInterimDuration388000JPY
Other noiPrior1InterimDuration4094000JPY
Other noiInterimDuration3885000JPY
Non operating incomePrior1InterimDuration40346000JPY
Non operating incomeInterimDuration13605000JPY
Interest expenses noePrior1InterimDuration6349000JPY
Interest expenses noeInterimDuration7895000JPY
Foreign exchange losses noePrior1InterimDuration21886000JPY
Foreign exchange losses noeInterimDuration61006000JPY
Other noePrior1InterimDuration9970000JPY
Other noeInterimDuration71000JPY
Non operating expensesPrior1InterimDuration38206000JPY
Non operating expensesInterimDuration68973000JPY
Ordinary incomePrior1InterimDuration3065617000JPY
Ordinary incomeInterimDuration3113687000JPY
Gain on sales of noncurrent assets eiPrior1InterimDuration－JPY
Gain on sales of noncurrent assets eiInterimDuration1338000JPY
Extraordinary incomePrior1InterimDuration－JPY
Extraordinary incomeInterimDuration1338000JPY
Income before income taxesPrior1InterimDuration3065617000JPY
Income before income taxesInterimDuration3115025000JPY
Income taxes currentPrior1InterimDuration978314000JPY
Income taxes currentInterimDuration1014566000JPY
Income taxes deferredPrior1InterimDuration37974000JPY
Income taxes deferredInterimDuration14463000JPY
Income taxesPrior1InterimDuration1016288000JPY
Income taxesInterimDuration1029029000JPY
Profit lossPrior1InterimDuration2049328000JPY
Profit lossInterimDuration2085996000JPY
Profit loss attributable to owners of parentPrior1InterimDuration2049328000JPY
Profit loss attributable to owners of parentInterimDuration2085996000JPY
Profit lossPrior1InterimDuration2049328000JPY
Profit lossInterimDuration2085996000JPY
Valuation difference on available for sale securities net of tax ociPrior1InterimDuration-573000JPY
Valuation difference on available for sale securities net of tax ociInterimDuration18161000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-06-30pass
balance sheet identityconsolidated 2025-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-06-30pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-07-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-07-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-07-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-07-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-07-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-07-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2025-06-30pass
statement vs summary · total assetsconsolidated 2025-12-31pass